Overview

Colchicine for Diabetic Nephropathy Trial

Status:
Unknown status
Trial end date:
2019-04-30
Target enrollment:
Participant gender:
Summary
Forty patients with diabetic nephropathy will be treated with colchicine up to 2 mg, or placebo, for 18 months. A follow up will be performed after 12 additional months. The primary outcome will be a significant reduction or stabilization of proteinuria during the 18 month treatment period.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sheba Medical Center
Collaborator:
D-Cure, Israel
Treatments:
Colchicine